Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
ELAN vs PETS vs ZTS vs CHWY vs WOOF
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Pharmaceuticals
Drug Manufacturers - Specialty & Generic
Specialty Retail
Specialty Retail
ELAN vs PETS vs ZTS vs CHWY vs WOOF — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Pharmaceuticals | Drug Manufacturers - Specialty & Generic | Specialty Retail | Specialty Retail |
| Market Cap | $11.99B | $48M | $36.86B | $9.80B | $752M |
| Revenue (TTM) | $4.89B | $195M | $9.51B | $12.35B | $5.96B |
| Net Income (TTM) | $-242M | $-55M | $2.64B | $151M | $9M |
| Gross Margin | 49.4% | 29.9% | 70.8% | 29.5% | 38.7% |
| Operating Margin | 9.0% | -11.1% | 37.9% | 1.3% | 2.0% |
| Forward P/E | 23.3x | — | 12.4x | 27.0x | 18.8x |
| Total Debt | $4.02B | $996K | $9.49B | $502M | $1.37B |
| Cash & Equiv. | $545M | $55M | $2.31B | $596M | $257M |
ELAN vs PETS vs ZTS vs CHWY vs WOOF — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 21 | May 26 | Return |
|---|---|---|---|
| Elanco Animal Healt… (ELAN) | 100 | 82.7 | -17.3% |
| PetMed Express, Inc. (PETS) | 100 | 6.0 | -94.0% |
| Zoetis Inc. (ZTS) | 100 | 56.6 | -43.4% |
| Chewy, Inc. (CHWY) | 100 | 23.2 | -76.8% |
| Petco Health and We… (WOOF) | 100 | 10.6 | -89.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ELAN vs PETS vs ZTS vs CHWY vs WOOF
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ELAN ranks third and is worth considering specifically for momentum.
- +99.9% vs ZTS's -42.7%
PETS lags the leaders in this set but could rank higher in a more targeted comparison.
ZTS carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 13 yrs, beta 0.90, yield 2.3%
- 107.3% 10Y total return vs ELAN's -33.3%
- Lower volatility, beta 0.90, current ratio 3.03x
- Beta 0.90, yield 2.3%, current ratio 3.03x
CHWY is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 6.4%, EPS growth 8.9%, 3Y rev CAGR 9.8%
- 6.4% revenue growth vs PETS's -17.2%
- Beta 0.70 vs ELAN's 1.42
Among these 5 stocks, WOOF doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 6.4% revenue growth vs PETS's -17.2% | |
| Value | Lower P/E (12.4x vs 27.0x) | |
| Quality / Margins | 27.8% margin vs PETS's -28.2% | |
| Stability / Safety | Beta 0.70 vs ELAN's 1.42 | |
| Dividends | 2.3% yield, 13-year raise streak, vs PETS's 0.4%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +99.9% vs ZTS's -42.7% | |
| Efficiency (ROA) | 17.5% ROA vs PETS's -54.9%, ROIC 26.9% vs -3.1% |
ELAN vs PETS vs ZTS vs CHWY vs WOOF — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
ELAN vs PETS vs ZTS vs CHWY vs WOOF — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ZTS leads in 2 of 6 categories
ELAN leads 1 • PETS leads 0 • CHWY leads 0 • WOOF leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ZTS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CHWY is the larger business by revenue, generating $12.3B annually — 63.3x PETS's $195M. ZTS is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to PETS's -28.2%. On growth, ELAN holds the edge at +14.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $4.9B | $195M | $9.5B | $12.3B | $6.0B |
| EBITDAEarnings before interest/tax | $957M | -$14M | $4.0B | $313M | $317M |
| Net IncomeAfter-tax profit | -$242M | -$55M | $2.6B | $151M | $9M |
| Free Cash FlowCash after capex | $315M | -$34M | $2.1B | $463M | $286M |
| Gross MarginGross profit ÷ Revenue | +49.4% | +29.9% | +70.8% | +29.5% | +38.7% |
| Operating MarginEBIT ÷ Revenue | +9.0% | -11.1% | +37.9% | +1.3% | +2.0% |
| Net MarginNet income ÷ Revenue | -4.9% | -28.2% | +27.8% | +1.2% | +0.2% |
| FCF MarginFCF ÷ Revenue | +6.4% | -17.4% | +22.5% | +3.8% | +4.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +14.9% | -25.5% | +1.9% | +8.6% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -15.4% | -4.7% | +0.7% | -79.4% | +81.6% |
Valuation Metrics
Evenly matched — PETS and WOOF each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 14.5x trailing earnings, ZTS trades at a 83% valuation discount to WOOF's 86.8x P/E. On an enterprise value basis, WOOF's 5.9x EV/EBITDA is more attractive than CHWY's 42.8x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $12.0B | $48M | $36.9B | $9.8B | $752M |
| Enterprise ValueMkt cap + debt − cash | $15.5B | -$5M | $44.0B | $9.7B | $1.9B |
| Trailing P/EPrice ÷ TTM EPS | -51.07x | -7.67x | 14.50x | 25.99x | 86.75x |
| Forward P/EPrice ÷ next-FY EPS est. | 23.29x | — | 12.43x | 27.02x | 18.76x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 1.21x | — | — |
| EV / EBITDAEnterprise value multiple | 16.59x | -0.98x | 10.78x | 42.76x | 5.89x |
| Price / SalesMarket cap ÷ Revenue | 2.54x | 0.21x | 3.89x | 0.83x | 0.13x |
| Price / BookPrice ÷ Book value/share | 1.82x | 0.56x | 11.63x | 38.99x | 0.68x |
| Price / FCFMarket cap ÷ FCF | 42.21x | — | 16.14x | 21.67x | 2.39x |
Profitability & Efficiency
Evenly matched — ZTS and CHWY each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
ZTS delivers a 62.4% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $-128 for PETS. PETS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ZTS's 2.85x. On the Piotroski fundamental quality scale (0–9), ZTS scores 7/9 vs PETS's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -3.6% | -127.8% | +62.4% | +38.8% | +0.8% |
| ROA (TTM)Return on assets | -1.8% | -54.9% | +17.5% | +4.8% | +0.2% |
| ROICReturn on invested capital | +1.9% | -3.1% | +26.9% | +28.0% | +2.9% |
| ROCEReturn on capital employed | +2.2% | -1.7% | +29.9% | +12.0% | +3.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 7 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.61x | 0.01x | 2.85x | 1.92x | 1.18x |
| Net DebtTotal debt minus cash | $3.5B | -$54M | $7.2B | -$93M | $1.1B |
| Cash & Equiv.Liquid assets | $545M | $55M | $2.3B | $596M | $257M |
| Total DebtShort + long-term debt | $4.0B | $996,000 | $9.5B | $502M | $1.4B |
| Interest CoverageEBIT ÷ Interest expense | -0.26x | -73.26x | 11.33x | 35.37x | 0.95x |
Total Returns (Dividends Reinvested)
ELAN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ELAN five years ago would be worth $7,301 today (with dividends reinvested), compared to $1,154 for WOOF. Over the past 12 months, ELAN leads with a +99.9% total return vs ZTS's -42.7%. The 3-year compound annual growth rate (CAGR) favors ELAN at 36.9% vs PETS's -42.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +6.6% | -30.3% | -29.8% | -29.4% | -3.5% |
| 1-Year ReturnPast 12 months | +99.9% | -36.5% | -42.7% | -38.3% | -14.1% |
| 3-Year ReturnCumulative with dividends | +156.5% | -80.5% | -49.8% | -29.2% | -73.0% |
| 5-Year ReturnCumulative with dividends | -27.0% | -82.1% | -44.4% | -66.7% | -88.5% |
| 10-Year ReturnCumulative with dividends | -33.3% | -47.8% | +107.3% | -32.4% | -90.6% |
| CAGR (3Y)Annualised 3-year return | +36.9% | -42.0% | -20.5% | -10.9% | -35.4% |
Risk & Volatility
Evenly matched — ELAN and CHWY each lead in 1 of 2 comparable metrics.
Risk & Volatility
CHWY is the less volatile stock with a 0.70 beta — it tends to amplify market swings less than ELAN's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ELAN currently trades 86.6% from its 52-week high vs CHWY's 48.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.42x | 1.25x | 0.90x | 0.70x | 0.92x |
| 52-Week HighHighest price in past year | $27.72 | $4.32 | $172.23 | $48.62 | $4.51 |
| 52-Week LowLowest price in past year | $10.75 | $1.57 | $85.31 | $22.74 | $2.24 |
| % of 52W HighCurrent price vs 52-week peak | +86.6% | +53.2% | +50.7% | +48.7% | +61.0% |
| RSI (14)Momentum oscillator 0–100 | 68.9 | 47.7 | 34.9 | 41.4 | 42.5 |
| Avg Volume (50D)Average daily shares traded | 4.6M | 81K | 3.7M | 7.7M | 2.6M |
Analyst Outlook
ZTS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ELAN as "Buy", ZTS as "Hold", CHWY as "Buy", WOOF as "Hold". Consensus price targets imply 76.3% upside for CHWY (target: $42) vs 16.1% for ELAN (target: $28). For income investors, ZTS offers the higher dividend yield at 2.29% vs PETS's 0.38%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | $27.88 | — | $143.00 | $41.71 | $3.59 |
| # AnalystsCovering analysts | 20 | — | 30 | 38 | 25 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% | +2.3% | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 13 | — | — |
| Dividend / ShareAnnual DPS | — | $0.01 | $2.00 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +8.8% | +9.6% | 0.0% |
ZTS leads in 2 of 6 categories (Income & Cash Flow, Analyst Outlook). ELAN leads in 1 (Total Returns). 3 tied.
ELAN vs PETS vs ZTS vs CHWY vs WOOF: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ELAN or PETS or ZTS or CHWY or WOOF a better buy right now?
For growth investors, Chewy, Inc.
(CHWY) is the stronger pick with 6. 4% revenue growth year-over-year, versus -17. 2% for PetMed Express, Inc. (PETS). Zoetis Inc. (ZTS) offers the better valuation at 14. 5x trailing P/E (12. 4x forward), making it the more compelling value choice. Analysts rate Elanco Animal Health Incorporated (ELAN) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ELAN or PETS or ZTS or CHWY or WOOF?
On trailing P/E, Zoetis Inc.
(ZTS) is the cheapest at 14. 5x versus Petco Health and Wellness Company, Inc. at 86. 8x. On forward P/E, Zoetis Inc. is actually cheaper at 12. 4x.
03Which is the better long-term investment — ELAN or PETS or ZTS or CHWY or WOOF?
Over the past 5 years, Elanco Animal Health Incorporated (ELAN) delivered a total return of -27.
0%, compared to -88. 5% for Petco Health and Wellness Company, Inc. (WOOF). Over 10 years, the gap is even starker: ZTS returned +107. 3% versus WOOF's -90. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ELAN or PETS or ZTS or CHWY or WOOF?
By beta (market sensitivity over 5 years), Chewy, Inc.
(CHWY) is the lower-risk stock at 0. 70β versus Elanco Animal Health Incorporated's 1. 42β — meaning ELAN is approximately 102% more volatile than CHWY relative to the S&P 500. On balance sheet safety, PetMed Express, Inc. (PETS) carries a lower debt/equity ratio of 1% versus 3% for Zoetis Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ELAN or PETS or ZTS or CHWY or WOOF?
By revenue growth (latest reported year), Chewy, Inc.
(CHWY) is pulling ahead at 6. 4% versus -17. 2% for PetMed Express, Inc. (PETS). On earnings-per-share growth, the picture is similar: Chewy, Inc. grew EPS 893. 4% year-over-year, compared to -169. 1% for Elanco Animal Health Incorporated. Over a 3-year CAGR, CHWY leads at 9. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ELAN or PETS or ZTS or CHWY or WOOF?
Zoetis Inc.
(ZTS) is the more profitable company, earning 28. 2% net margin versus -4. 9% for Elanco Animal Health Incorporated — meaning it keeps 28. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZTS leads at 38. 0% versus -0. 7% for PETS. At the gross margin level — before operating expenses — ZTS leads at 70. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ELAN or PETS or ZTS or CHWY or WOOF more undervalued right now?
On forward earnings alone, Zoetis Inc.
(ZTS) trades at 12. 4x forward P/E versus 27. 0x for Chewy, Inc. — 14. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CHWY: 76. 3% to $41. 71.
08Which pays a better dividend — ELAN or PETS or ZTS or CHWY or WOOF?
In this comparison, ZTS (2.
3% yield), PETS (0. 4% yield) pay a dividend. ELAN, CHWY, WOOF do not pay a meaningful dividend and should not be held primarily for income.
09Is ELAN or PETS or ZTS or CHWY or WOOF better for a retirement portfolio?
For long-horizon retirement investors, Zoetis Inc.
(ZTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 2. 3% yield, +107. 3% 10Y return). Both have compounded well over 10 years (ZTS: +107. 3%, ELAN: -33. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ELAN and PETS and ZTS and CHWY and WOOF?
These companies operate in different sectors (ELAN (Healthcare) and PETS (Healthcare) and ZTS (Healthcare) and CHWY (Consumer Cyclical) and WOOF (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ELAN is a mid-cap quality compounder stock; PETS is a small-cap quality compounder stock; ZTS is a mid-cap deep-value stock; CHWY is a small-cap quality compounder stock; WOOF is a small-cap quality compounder stock. ZTS pays a dividend while ELAN, PETS, CHWY, WOOF do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.